TECHNOLOGY COST SHOULD BE FACTOR IN NATIONAL COVERAGE DECISIONS, PPRC SUGGESTS; NEW COVERAGE CATEGORY FOR EXPERIMENTAL TREATMENTS ALSO SOUGHT
This article was originally published in The Gray Sheet
Executive Summary
National coverage decisions for medical technology should be made on the basis of cost as well as safety and efficacy considerations, the Physician Payment Review Commission suggests in its 1994 annual report submitted to Congress March 31.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.